The expression of haematopoietic genes (RUNX1, GATA2 and MYB) and the generation of CD43+ HPCs were impaired by Cilengitide treatment at Days 2‐4, but not at Days 4‐6 (Figure 5A‐C), suggesting that αvβ3 and αvβ5 inhibition impaired HE development, but not EHT. The gene discussed is RUNX1; the disease is essential hypertension, genetic.